Panelists discuss how the port delivery system (PDS) refill procedure, while performed in an office setting, involves a different technique of accessing and replenishing the implant’s drug reservoir ...

Investigators from the Cleveland Clinic Cole Eye Institute, Cleveland, reported the results of a study that identified macular structural and vascularity changes in adults who had been born ...

Dr Jordan Graff highlights key steps in implanting the port delivery system, emphasizing incision and closure techniques with video clips.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye. AI Optics, an ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular degeneration (nAMD) in eyes with geographic atrophy (GA) found that GA can ...

Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and ...

Home-stored anti-VEGF drugs face risks from temperature changes, pointing to a need to protect efficacy and avoid dangerous contamination. A European study found that temperature changes have the ...

Apellis has announced the Therapeutic Goods Administration (TGA) in Australia has approved pegcetacoplan (Syfovre) for the every-other-month treatment of adult patients with geographic atrophy (GA) ...

Panelists discuss how patients experiencing frequent anti-VEGF treatment burdens with 4- to 8-week intervals between injections are ideal candidates for PDS as an alternative delivery method.

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa. Clinical stage biopharmaceutical company Nacuity ...

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard ...